EP4460299A4 - Verfahren und zusammensetzungen zur induzierung von ferroptose in vivo - Google Patents

Verfahren und zusammensetzungen zur induzierung von ferroptose in vivo

Info

Publication number
EP4460299A4
EP4460299A4 EP22919247.1A EP22919247A EP4460299A4 EP 4460299 A4 EP4460299 A4 EP 4460299A4 EP 22919247 A EP22919247 A EP 22919247A EP 4460299 A4 EP4460299 A4 EP 4460299A4
Authority
EP
European Patent Office
Prior art keywords
ferroptose
vivo
compositions
industrial
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22919247.1A
Other languages
English (en)
French (fr)
Other versions
EP4460299A2 (de
Inventor
Vasanthi Viswanathan
Jr John Kittridge Eaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kojin Therapeutics Inc
Original Assignee
Kojin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kojin Therapeutics Inc filed Critical Kojin Therapeutics Inc
Publication of EP4460299A2 publication Critical patent/EP4460299A2/de
Publication of EP4460299A4 publication Critical patent/EP4460299A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22919247.1A 2022-01-07 2022-12-22 Verfahren und zusammensetzungen zur induzierung von ferroptose in vivo Pending EP4460299A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263297651P 2022-01-07 2022-01-07
PCT/US2022/082270 WO2023133053A2 (en) 2022-01-07 2022-12-22 Methods and compositions for inducing ferroptosis in vivo

Publications (2)

Publication Number Publication Date
EP4460299A2 EP4460299A2 (de) 2024-11-13
EP4460299A4 true EP4460299A4 (de) 2026-03-25

Family

ID=87074112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22919247.1A Pending EP4460299A4 (de) 2022-01-07 2022-12-22 Verfahren und zusammensetzungen zur induzierung von ferroptose in vivo

Country Status (2)

Country Link
EP (1) EP4460299A4 (de)
WO (1) WO2023133053A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118845757B (zh) * 2024-09-25 2025-01-28 深圳市利云德生物技术有限公司 一种治疗肝癌的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1736486A (zh) * 2005-08-05 2006-02-22 孔庆忠 一种抗癌植入剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
US20230000896A1 (en) * 2019-12-09 2023-01-05 President And Fellows Of Harvard College Aldh3a2 inhibition and ferroptosis induction for cancer therapy
JP2023509359A (ja) * 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
JP2023518027A (ja) * 2020-03-13 2023-04-27 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Ｇｐｘ４化合物及び組成物、並びにそれを使用する治療方法
US11541116B1 (en) * 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1736486A (zh) * 2005-08-05 2006-02-22 孔庆忠 一种抗癌植入剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
K. SHAHANI ET AL: "Injectable Sustained Release Microparticles of Curcumin: A New Concept for Cancer Chemoprevention", CANCER RESEARCH, vol. 70, no. 11, 11 May 2010 (2010-05-11), pages 4443 - 4452, XP055404553, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-09-4362 *
LACHAIER EMMA ET AL: "Sorafenib Induces Ferroptosis in Human Cancer Cell Lines Originating from Different Solid Tumors", 1 January 2014 (2014-01-01), pages 1 - 6, XP093336810, Retrieved from the Internet <URL:http://ar.iiarjournals.org/lookup/pmidlookup?view=long&pmid=25368241> *
NIU BOYI ET AL: "Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 277, 30 August 2021 (2021-08-30), XP086797343, ISSN: 0142-9612, [retrieved on 20210830], DOI: 10.1016/J.BIOMATERIALS.2021.121110 *
WANG JUNXIAO ET AL: "Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging", FRONTIERS IN ONCOLOGY, vol. 11, 26 August 2021 (2021-08-26), XP093335425, ISSN: 2234-943X, Retrieved from the Internet <URL:https://pmc.ncbi.nlm.nih.gov/articles/PMC8426437/pdf/fonc-11-743055.pdf> DOI: 10.3389/fonc.2021.743055 *
ZHENG LAN ET AL: "Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy", BIOMATERIALS, vol. 216, 2019, XP085723814, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2019.05.031 *

Also Published As

Publication number Publication date
WO2023133053A3 (en) 2023-09-28
EP4460299A2 (de) 2024-11-13
WO2023133053A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
EP4157359A4 (de) Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von serpina1
EP4153771A4 (de) Zusammensetzungen und verfahren zur dna-cytosin-carboxymethylierung
EP4486901A4 (de) Zusammensetzungen und verfahren zur genomeditierung
EP4243771A4 (de) Zusammensetzungen und verfahren zur schnellen infusion
EP4182289A4 (de) Verbesserte verfahren und zusammensetzungen zur verarbeitung von gülle
EP4412621A4 (de) Zusammensetzungen und verfahren zur verbesserten proteinproduktion
EP4125336A4 (de) Zusammensetzungen und verfahren zur flüssigkeitsvermittelten abgabe von pollen
EP4143582A4 (de) Zusammensetzungen und verfahren zur identifizierung von nanokörpern und nanokörperaffinitäten
EP4192958A4 (de) Zusammensetzungen und verfahren zur erhöhung der proteinexpression
EP4419677A4 (de) Dna-zusammensetzungen und zugehörige verfahren
EP4178975A4 (de) Zusammensetzungen und verfahren zur auflösung von proteinaggregaten
EP4307898A4 (de) Zusammensetzungen und verfahren zur dekontamination von oberflächen
EP4171606A4 (de) Zusammensetzungen und verfahren zur behandlung von covid-19
EP4413363A4 (de) Zusammensetzungen und verfahren zur erkennung von cadherin-17-protein
EP4304596A4 (de) Zusammensetzungen und verfahren zur behandlung von polycythämie
EP4087919A4 (de) Zusammensetzungen und verfahren zur herkunftsbestimmung
EP4457356A4 (de) Zusammensetzungen und verfahren zur identifizierung von genfusionen
EP4460299A4 (de) Verfahren und zusammensetzungen zur induzierung von ferroptose in vivo
EP4355331A4 (de) Verfahren und zusammensetzungen zur melanombehandlung
EP4398938A4 (de) Zusammensetzungen und verfahren zur stabilisierung von biomolekülen
EP4352085A4 (de) Verfahren und zusammensetzungen zur neuronalen reprogrammierung
EP4352235A4 (de) Verfahren und zusammensetzungen zur veränderung der proteinakkumulation
EP4536597A4 (de) Zusammensetzungen und verfahren zur ausflockung
EP4423254A4 (de) Zusammensetzungen und verfahren zur förderung der in-vitro-reifung von zellen
EP4490300A4 (de) Zusammensetzungen und verfahren zur expression von therapeutika

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240726

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/404 20060101AFI20251126BHEP

Ipc: A61K 9/00 20060101ALI20251126BHEP

Ipc: A61P 35/00 20060101ALI20251126BHEP

Ipc: G01N 33/574 20060101ALI20251126BHEP

Ipc: A61K 31/33 20060101ALI20251126BHEP

Ipc: A61K 31/437 20060101ALI20251126BHEP

Ipc: A61K 31/496 20060101ALI20251126BHEP

Ipc: A61K 31/517 20060101ALI20251126BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20260223